Physician profile
Leah C Silver
NPI 1063662443
$32,097.76
in general payments reported to CMS, 2019-2025
57 companies · $1,023 in 2025
The $1,023 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $1,163 · 2021: $4,240 · 2022: $5,701 · 2023: $11K · 2024: $8,956 · 2025: $1,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $9,541 · Travel and Lodging: $701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,400.00 |
| Food and Beverage | $9,540.80 |
| Travel and Lodging | $701.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $13,770.28 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $4,015.89 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $1,305.26 | 2020-2024 | Repatha |
| Novo Nordisk INC | $1,276.02 | 2020-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,005.62 | 2020-2024 | Trelegy Ellipta, Shingrix, Nucala |
| Lilly USA, LLC | $880.40 | 2020-2024 | Mounjaro, Jardiance, Trulicity |
| Biohaven Pharmaceutical Holding Company LTD. | $772.67 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $732.25 | 2021-2024 | Rexulti |
| Corcept Therapeutics | $728.42 | 2022-2024 | Korlym |
| Axsome Therapeutics, INC. | $679.78 | 2022-2024 | Auvelity |
| Novartis Pharmaceuticals Corporation | $663.26 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $492.30 | 2020-2023 | Verquvo, Belsomra |
| Biohaven Pharmaceuticals, INC. | $483.03 | 2020-2021 | |
| Nevro Corp. | $482.47 | 2022-2024 | Senza |
| Abbott Laboratories | $411.03 | 2021-2023 | Freestyle Libre 3 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.